Array Technologies Inc (ARRY)

[north40000]

I do/did what you say, but own 100x more AMRN than ARRY. Insurance/PBM preference in formularies for Vascepa is a portent for AMRN commercial success and consequent physician/consumer education. V's scrips continue to rise for its multiple off-label uses/effects. My own DES disappeared in 3-4 days after initiating therapy, far faster and cheaper than AGN's Restasis or Shire's recently FDA-approved product.

Further conversation will be on AMRN's board... read the links to EPA effects provided by zumantu and JL there on a daily basis.